

Phase 4, open-label, single-arm study.
Patients with Crohn's disease newly diagnosed who were biologic-naïve received vedolizumab (300mg on day 0,2,6 and q8w)+ adalimumab (160 mg, 80mg w2 and 40mg eow) and methotrexate (15mg every week).

Primary endpoints: Endoscopic remission at week 26 (SES-CD \leq 2).

Results: N=55

- At week 26, 35.5% were in endoscopic remission.
- Clinical remission at week 10 and 26 were 61.8% and 54.5% respectively.

Conclusion:

Combination therapy resulted in endoscopic and clinical remission at week 26 in 34.5% and 54.5% of patients, respectively, with no safety signal related to the treatment regimen.

